Skip to main content

Advertisement

SpringerLink
Log in

Isthmus-Preserving Total Bilobectomy: An Adequate Operation for C-Cell Hyperplasia

  • Published:
World Journal of Surgery Aims and scope Submit manuscript

Abstract

Background

Autopsy studies show that C cells deriving from the ultimobranchial body and migrating into the thyroid do not reach the isthmus region and are distributed along the vertical axes of thyroid lobes. This was confirmed in a surgical series of 58 patients (34 with preoperatively normal and 24 with elevated serum calcitonin) where no calcitonin-positive cells were demonstrable immunohistochemically within separately investigated isthmi. Consequently, isthmus-preserving total bilateral lobectomy (IPTB) may be regarded as an adequate surgical procedure for C-cell hyperplasia (CCH).

Patients and Methods

IPTB was performed from October 2001 to December 2004 in 64 patients, 59 patients with nodular goiter and slightly to moderately elevated serum calcitonin (stimulated under 500 pg/ml) (group A, apparently sporadic cases) and in 5 patients undergoing prophylactic surgery for hereditary medullary thyroid carcinoma (MTC) with intermediate- or low-risk RET mutations (non-634) (group B). The surgical procedure focused on meticulous total extracapsular resection of both thyroid lobes, preservation of an isthmus remnant of about 3 ml (smaller in children), and histologic workup of the border zones of resection in addition to that of the completely removed lobes. When malignancy could be proven intraoperatively (7 patients) or when the isthmus turned out to contain nodular lesions (4 patients), completion total thyroidectomy (plus lymphadenectomy) was performed as a one-stage procedure. Second-stage total thyroidectomy was performed in 3 cases. Thus, IPTB was the definitive surgical procedure in 50 patients (45 of group A and all 5 of group B).

Results

In all of the 50 definite IPTB cases, postoperative serum calcitonin was below the measurable limit (2 pg/ml); stimulated calcitonin was below the measurable limit in 47 (including all of group B) and was measurable in 3 sporadic cases in a lower-normal range between 2.4 and 3.5 pg/ml. Genetic screening of the apparently sporadic cases with CCH was positive in one (codon 791). The risk of recurrent laryngeal nerve paralysis seems not to be elevated (0% permanent); permanent hypocalcemia occurred in 1 patient (2%). Follow-up data of 37 patients, median 18 (6–36) months, showed continuously nonmeasurable serum calcitonin with one exception, where it was in the normal range after 18 months. All IPTB patients are still under substitution therapy with L-thyroxine (median 125 μg/day) with decreasing tendency in all 3 children after prophylactic operation, the latter also showing an increasing volume of well-vascularized isthmi (from 1.5 to 2.5 ml).

Conclusion

IPTB reliably removes all C cells. There may not be need for total thyroidectomy (TTx) in cases with CCH. When necessary, completion TTx can be performed easily without additional risk. IPTB leaves a functionally relevant remnant, corresponding to that of a subtotal resection. This might be of importance especially for prophylactic surgery in children where the isthmus can compensate for the loss of thyroid function with time.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1.
Figure 2.
Figure 3.

Similar content being viewed by others

References

  1. Pacini F, Fontanelli M, Fugazzola L, et al. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1994;78:826–829

    Article  CAS  PubMed  Google Scholar 

  2. Rieu M, Lame MC, Richard A, et al. Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnosis evaluation of thyroid nodules. Clin Endocrinol 1995;42:453–460

    CAS  Google Scholar 

  3. Vierhapper H, Raber W, Bieglmayer C, et al. Routine measurement of plasma calcitonin in nodular thyroid diseases. J Clin Endokrinol Metab 1997;82(5):1589–1593

    Article  CAS  Google Scholar 

  4. Niccoli P, Wion-Barbot N, Caron P, et al. Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. J Clin Endocrinol Metab 1997;82:338–341

    Article  Google Scholar 

  5. Kaserer K, Scheuba C, Neuhold N, et al. C-cell hyperplasia and medullary thyroid carcinoma in patients routinely screened for serum calcitonin. Am J Surg Pathol 1998;22(6):722–728

    Article  CAS  PubMed  Google Scholar 

  6. Henry JF, et al. Latent subclinical medullary thyroid Carcinoma: Diagnosis and treatment. World J Surg 1998;22:752–757

    Article  CAS  PubMed  Google Scholar 

  7. Özgen AG, Hamulu F, Bayraktar F, et al. Evaluation of routine basal serum calcitonin measurement for early diagnosis of medullary thyroid carcinoma in seven hundred seventy-three patients with nodular goiter. Thyroid 1999;9:579–582

    Article  PubMed  Google Scholar 

  8. Hahm JR, Lee MS, Min YK, et al. Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. Thyroid 2001;11(1):73–80

    Article  CAS  PubMed  Google Scholar 

  9. Iacobone M, Niccoli-Sire P, Sebag F, et al. Can sporadic medullary thyroid carcinoma be biochemically predicted? Prospective analysis of 66 operated patients with elevated serum calcitonin levels. World J Surg 2002;26(8):886–890

    Article  PubMed  Google Scholar 

  10. Mirallié E, Iacobone M, Sebag F, et al. Results of surgical treatment of sporadic medullary thyroid carcinoma following routine measurement of serum calcitonin. Eur J Surg Oncol 2004;30:790–795

    Article  PubMed  Google Scholar 

  11. Scheuba C, Kaserer K, Weinhausl A, et al. Is medullary thyroid cancer predictable? A prospective study of 86 patients with abnormal pentagastrin tests. Surgery 1999;126(6):1089–1095

    Article  CAS  PubMed  Google Scholar 

  12. Karges W, Dralle H, Raue F, et al. Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation. Exp Clin Endocrinol Diabetes 2004;112:52–58

    Article  CAS  PubMed  Google Scholar 

  13. Lips CJM, et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. New Engl J Med 1994;331(13):828–835

    Article  CAS  PubMed  Google Scholar 

  14. Dralle H, Gimm O, Simon D, et al. Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J Surg 1998;22:744–751

    Article  CAS  PubMed  Google Scholar 

  15. Wahl RA, Röher HD. Surgery of C cell carcinoma of the thyroid. Prog Surg 1988;19:100–112

    Google Scholar 

  16. Brandi ML, Gogel RF, Angeli A, et al. Consensus: Guide lines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658–5671

    Article  CAS  PubMed  Google Scholar 

  17. Machens A, Niccoli-Sire P, Hoegel J, et al. For the European multiple endocrine neoplasia study group. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 2003;349:1517–1525

    Article  CAS  PubMed  Google Scholar 

  18. Gimm O, Ukkat J, Niederle BE, et al. Timing and extent of surgery in patients with familial medullary thyroid carcinoma/multiple endocrine neoplasia 2A-related RET mutations not affecting codon 634. World J Surg 2004;28:1312–1316

    Article  PubMed  Google Scholar 

  19. Sadler TW, Langman J. Medizinische Embryologie Die normale menschliche Entwicklung und ihre Fehlbildungen. Thieme 2003;10:330–335

    Google Scholar 

  20. Wolfe HJ, Voelkel EF, Tashjian AH. Distribution of calcitonin-containing cells in the normal adult human thyroid gland: A correlation of morphology with peptide content. J Clin Endocrinol Metab 1974;38:688–694

    Article  CAS  PubMed  Google Scholar 

  21. Wolfe HJ, DeLellis RA, Voekel EF, et al. Distribution of calcitonin-containing cells in the normal neonatal human thyroid gland: A correlation of morphology with peptide content. J Clin Endocrinol Metab 1975;41:1076–1081

    CAS  PubMed  Google Scholar 

  22. Gmunder-Lehner RB, Okamoto E, Hedinger C. Distribution of C cells in the human thyroid gland. Schweiz Med Wochenschr 1983;113(39):1385–1394

    CAS  PubMed  Google Scholar 

  23. Biddinger PW, Brennan MF, Rosen PP. Symptomatic C-cell hyperplasia associated with chronic lymphocytic thyroiditis. Am J Surg Pathol 1991;15(6):599–604

    Article  CAS  PubMed  Google Scholar 

  24. Guyétant S, Rousselet MC, Durigon M, et al. Experimental studies sex-related C cell hyperplasia in the normal human thyroid: A quantitative autopsy study. J Clin Endocrinol Metab 1997;82:42–47

    Article  PubMed  Google Scholar 

  25. Gibson WGH, Peng T-C, Croker BP. Age-associated C-cell hyperplasia in the human Thyroid. Am J Pathol 1982;106:388–393

    CAS  PubMed  Google Scholar 

  26. Scopsi L, Di Palma S, Ferrari C, et al. C-Cell hyperplasia accompanying thyroid diseases other than medullary carcinoma: an immunocytochemical study by means of antibodies to calcitonin and somatostatin. Mod Pathol 1991;4,3:297–304

    Google Scholar 

  27. Perry A, Molberg K, Albores-Saavedra J. Physiologic versus neoplastic C-cell hyperplasia of the thyroid separation of distinct histologic and biologic entities. Am Cancer Soc 1996;77:750–756

    CAS  Google Scholar 

  28. Kaserer K, Scheuba C, Neuhold N, et al. Sporadic versus familiar medullary thyroid microcarcinoma: a histopathologic study of 50 consecutive patients. Am J Surg Pathol 2001;25(10):1245–1251

    Article  CAS  PubMed  Google Scholar 

  29. Hinze R, Gimm O, Brauckhoff M, et al. “Physiologische” und „ „neoplastische” C-Zell-hyperplasien der Schilddrüse Morphologisch und biologisch distinkte Entitäten? Pathologe 2001;22:259–265

    Article  CAS  PubMed  Google Scholar 

  30. Li Volsi VA. Editorial: C cell hyperplasia/neoplasia. J Clin Endocrinol Metab 1997;82(1):39–41

    Article  CAS  Google Scholar 

  31. Juaneda C, Dumont Y, Quirion R. The molecular pharmacology of CGRP and related peptide receptor subtypes. Trends Pharmacol Sci 2000;21:432–438

    Article  CAS  PubMed  Google Scholar 

  32. Pondel M. Calcitonin and calcitonin receptors: bone and beyond. J Exp Pathol 2000;81:405–422

    Article  CAS  Google Scholar 

  33. Mason RT, Shulkes A, Zajac JD, et al. Basal and stimulated release of calcitonin gene-related peptide (CGRP) in patients with medullary thyroid carcinoma. Clin Endocrinol 1986;25:675–685

    CAS  Google Scholar 

  34. Williams ED, Ponder BJ, Craig RK. Immunohistochemical study of calcitonin gene-related peptide in human medullary carcinoma and C cell hyperplasia. Clin Endocrinol 1987;27:107–114

    CAS  Google Scholar 

  35. Schmid KW, Kirchmair R, Ladurner D, et al. Immunohistochemical comparison of chromogranins A and B and secretogranin II with calcitonin and calcitonin gene-related peptide expression in normal, hyperplastic and neoplastic C-cells of the human thyroid. Histopathology 1992; 21:225–232

    CAS  PubMed  Google Scholar 

  36. Vierhapper H, Bieglmayer C, Heinze G, et al. Frequency of RET proto-oncogene mutations in patients with normal and with moderately elevated pentagastrin-stimulated serum concentrations of calcitonin. Thyroid 2004;14(8):580–583

    Article  CAS  PubMed  Google Scholar 

  37. Frank-Raue K. Nachsorge nach prophylaktischer Thyreoidektomie bei Kindern und Jugendlichen bei MEN 2 Syndrom. In: Sutter T, Brauckhoff M, Dralle H, editors. Aktuelle Chirurgie endokriner Erkrankungen und hereditärer Tumoren. Gutenberg Verlag Leipzig

  38. Gemsenjäger E. Die chirurgische Behandlung der autonomen Knotenstruma. Schweiz Med Wschr 1992;122:687–692

    PubMed  Google Scholar 

  39. Wahl RA, Rimpl I, Saalabian S, Schabram J. Differentiated operative therapy of thyroid autonomy (Plummer’s disease). Exp Clin Endocrinol Diabetes (Section Schilddrüse 1998) 1998;106(4):78–84

    Article  Google Scholar 

  40. Wiener JP. Is partial thyroidectomy definitive treatment for Plummer’s disease (autonomous goitre)? Clin Nucl Med 1983;8:78–82

    CAS  PubMed  Google Scholar 

  41. Rosato L, Avenia N, Bernante P, De Palma M, Gulino G, Nasi PG, Pelizzo MR, Pezzulo L. Complications of thyroid surgery: analysis of a multicentric study on 14,934 patients operated on in Italy over 5 years. World J Surg 2004;28(3):271–276

    Article  PubMed  Google Scholar 

  42. Thomusch O, Machens A, Sekulla C, et al. Multivariate analysis of risk factors for postoperative complications in benign goiter surgery: prospective multicenter study in Germany. World J Surg 2000;24:1335–1341

    Article  CAS  PubMed  Google Scholar 

  43. Schabram J, Wahl RA. Clinical relevance of slightly elevated calcitonin levels in non hereditary, non-MEN thyroid disease. Viszeralchirurgie 2001;36:1–5

    Article  Google Scholar 

  44. Peix JL, Braun P, Saadat M, et al. Occult micro medullary thyroid carcinoma: therapeutic strategy and follow-up. World J Surg 2000;24:1373–1376

    Article  CAS  PubMed  Google Scholar 

  45. Raffel A, Cupisti K, Krausch M, et al. Incidentally found medullary thyroid cancer: treatment rationale for small tumors. World J Surg 2004;28:397–401

    Article  PubMed  Google Scholar 

  46. Raue F, Frank-Raue K. Subclinical hypo- and hyperthyroidism—diagnostic and therapeutic implications. Viszeralchirurgie 2005;40:170–173

    Article  Google Scholar 

  47. Stelfox HT, Ahmed SB, Fiskio J, et al. An evaluation of the adequacy monitoring of thyroid replacement therapy. J Eval Clin Pract 2004;10:525–530

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Bürgerhospital Frankfurt am Main, Nibelungenallee 37 - 41, 60318, Frankfurt am Main, Germany

    Robert Arnulf Wahl MD, Christian Vorländer MD, Johanna Pedall & Martin Spitza MD

  2. Institute of Pathology, University of Frankfurt am Main, Theodor-Stern-Kai 5 - 7, 60590, Frankfurt am Main, Germany

    Susanne Kriener MD & Martin-Leo Hansmann MD

Authors
  1. Robert Arnulf Wahl MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christian Vorländer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Susanne Kriener MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Johanna Pedall
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Martin Spitza MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Martin-Leo Hansmann MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert Arnulf Wahl MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wahl, R.A., Vorländer, C., Kriener, S. et al. Isthmus-Preserving Total Bilobectomy: An Adequate Operation for C-Cell Hyperplasia. World J. Surg. 30, 860–871 (2006). https://doi.org/10.1007/s00268-005-0424-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00268-005-0424-z

Keywords

Search

Navigation